Wednesday, September 16, 2026Latest filing Sep 14, 2026

DXCM Congressional Stock Trades

DEXCOM, INC. CMN

Last disclosed trade Jun 30

Every disclosed trade in DXCM by members of Congress under the STOCK Act, parsed by Coldpine. Informational only, sourced from public filings. Not investment advice.

Sample · the intelligence layer

Coldpine signal scoreA 0-1 composite from four weighted factors: disclosure speed, trade size, cluster activity (multiple members buying the same name), and the member’s track record. ≥ 0.65 is the high-conviction tier; ≥ 0.50 is moderate. Trades from trust-managed members are penalized (× 0.2 multiplier). It’s research, not a recommendation.

Tina Smith · Sold $DXCM · May 7 · $100K–$250K

0.72HIGH
Disclosure speedx 0.251.00
Trade sizex 0.250.75
Cluster activityx 0.150.70

2 other members traded this name in the same window.

Track recordx 0.35default0.50

Coldpine’s read

Smith's Finance Committee seat carries jurisdiction over healthcare and Medicare policy that touches medical-device makers like DexCom. The spouse-owned sale of $100K–$250K clears at the higher end of typical disclosed ranges. Two other members sold DXCM in the same direction within 30 days, and the 3-day disclosure lag means the market has had limited time to absorb the filing.

Every disclosed trade in the database gets this treatment: a four-factor score and a written read from Coldpine’s AI-based analysis. Informational only, not investment advice. Create a free account for every scored trade →

Follow $DXCM

Get notified when any member of Congress trades $DXCM. Free, no card, no spam.

Follow free →
35
Disclosed trades
21
Buys
14
Sells
7
Members trading

The record on $DXCM

Coldpine has parsed 35 disclosed trades in $DXCM by 7 members of Congress, drawn from 24 periodic transaction reports dated Aug 21, 2023 through Jun 30, 2026. That is 32 trades from House members and 3 trades from senators, filed 23 by Democrats and 12 by Republicans.

Of the 35 trades with a known filing lag, every one was reported inside the STOCK Act's 45-day window. The median lag was 25 days. The longest was 38 days: a $DXCM purchase by Michael T. McCaul dated Aug 4, 2025, disclosed Sep 11, 2025. How late filing is measured across all of Congress is in the late-filers study.

29 of the 33 trades that list an account holder (88%) were reported under a spouse, dependent child, or joint account rather than the member directly.

Rohit Khanna filed the most $DXCM purchases (16), and Michael T. McCaul the most sales (5).

Activity peaked in 2025 with 12 trades. The busiest single month was May 2026, when 2 different members disclosed $DXCM trades.

Across the 21 purchases Coldpine can price, $DXCM moved +1.18% on average between the trade date and the disclosure date, against +3.48% for the S&P 500 over the same windows. The stock was higher at disclosure than at the trade in 48% of those purchases. That is a record of what already happened, not a forecast. Method: what stocks do before Congress discloses.

Members who trade DXCM

Recent disclosed trades in DXCM

DateMemberTypeAmount
Jun 30Rohit Khanna(CA)sell$1K–$15K
May 7Tina Smith(MN)sell$100K–$250K
May 7Michael T. McCaul(TX)sell$1K–$15K
Apr 29Tina Smith(MN)sell$100K–$250K
Apr 24Rohit Khanna(CA)sell$1K–$15K
Apr 13Rohit Khanna(CA)buy$1K–$15K
Feb 4Michael T. McCaul(TX)sell$1K–$15K
Jan 26John Boozman(AR)buy$1K–$15K
Dec 12Rohit Khanna(CA)buy$1K–$15K
Dec 5Rohit Khanna(CA)buy$1K–$15K
Oct 27Michael T. McCaul(TX)sell$15K–$50K
Sep 29Rohit Khanna(CA)sell$1K–$15K
Aug 21Michael T. McCaul(TX)sell$1K–$15K
Aug 7Michael T. McCaul(TX)buy$1K–$15K
Aug 4Michael T. McCaul(TX)buy$1K–$15K
May 28Rohit Khanna(CA)buy$1K–$15K
May 15Rob Bresnahan(PA)buy$1K–$15K
Apr 8Michael T. McCaul(TX)buy$50K–$100K
Apr 8Rob Bresnahan(PA)sell$1K–$15K
Mar 13Michael T. McCaul(TX)sell$15K–$50K

Showing 20 of 35 disclosed trades.

Sign up free for the full history, signal scores, the price-vs-trades chart, and Coldpine's read (the AI narrative on each trade).

Create a free account

Data sourced from public STOCK Act disclosures. Coldpine is a publisher of intelligence on congressional disclosures, not an investment adviser. See full history and scores, free with an account →